Pharmacological Reduction of Right Ventricular Enlargement

NCT ID: NCT04345796

Last Updated: 2025-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-15
• Study Completion Date: 2024-06-03

Brief Summary

Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart failure (HF), mitral valve (MV) disease or atrial fibrillation. Regardless of left ventricular (LV) function or pulmonary artery pressure, presence of moderate or greater functional TR is associated with poor prognosis. When a patient develops functional TR, it causes RV dilation and tricuspid annular enlargement, which also lead to deterioration of TR. A vicious cycle of significant TR, RV volume overload, tricuspid annular dilation and consequent aggravation of TR is accepted as a main determinant of the poor clinical outcome of patients with TR. Therefore, therapies that induce reverse remodeling of the RV and consequently reduce TR, may improve clinical outcomes. However, there have been no proven medical therapies for TR. The investigators hypothesize that carvedilol or empagliflozin is effective on improving RV remodeling in patients with functional severe TR and try to examine this hypothesis in a multicenter, 2x2 factorial, and randomized comparison study using cardiac MRI.

Detailed Description

Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart failure (HF), mitral valve (MV) disease or atrial fibrillation. The prevalence of functional TR was reported to be 25-64% in patients with either ischemic or non-ischemic cardiomyopathy. Regardless of left ventricular (LV) function or pulmonary artery pressure, presence of moderate or greater functional TR is associated with poor prognosis. When a patient develops functional TR, it causes RV dilation and tricuspid annular enlargement, which also lead to deterioration of TR. A vicious cycle of significant TR, RV volume overload, tricuspid annular dilation and consequent aggravation of TR is accepted as a main determinant of the poor clinical outcome of patients with TR. Because the quantitative assessment of RV size and function using echocardiography is often limited due to the complex geometry of RV, cardiac magnetic resonance imaging (MRI) has emerged as a gold standard for evaluating RV volume and function with excellent accuracy and reproducibility. The investigators previously reported that RV end-systolic volume index (ESVI) and RV end-diastolic volume index (EDVI) measured by MRI were significantly larger in severe TR patients, and also found that preoperative RV ESVI and RV ejection fraction (EF) on MRI were independent predictors of cardiac death and postoperative adverse events in patients who underwent TV surgery for severe functional TR. Therefore, therapies that induce reverse remodeling of the RV and consequently reduce TR, may improve clinical outcomes. However, there have been no proven medical therapies for TR. The morbidity and mortality of patients with functional TR remain high and novel therapeutic agents are needed to improve the prognosis of patients with functional TR. The investigators hypothesize that carvedilol or empagliflozin is effective on improving RV remodeling in patients with functional severe TR and try to examine this hypothesis in a multicenter, 2x2 factorial, and randomized comparison study using cardiac MRI.

Conditions

Tricuspid Regurgitation; Right Ventricular Dilatation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

carvedilol+empagliflozin

Patients will receive carvedilol SR 16mg and empagliflozin 10mg qd.

Group Type: ACTIVE_COMPARATOR

Carvedilol+Empagliflozin

Intervention Type: DRUG

Group A

carvedilol alone

Patients will receive carvedilol SR 16mg alone.

Group Type: ACTIVE_COMPARATOR

Carvedilol

Intervention Type: DRUG

Group B

empagliflozin alone

Patients will receive empagliflozin 10mg and matching placebo of carvedilol.

Group Type: ACTIVE_COMPARATOR

Empagliflozin

Intervention Type: DRUG

Group C

placebo

Patients will receive matching placebo of carvedilol.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Group D

Interventions

Carvedilol+Empagliflozin

Group A

Intervention Type: DRUG

Carvedilol

Group B

Intervention Type: DRUG

Empagliflozin

Group C

Intervention Type: DRUG

Placebo

Group D

Intervention Type: DRUG

Other Intervention Names

Dilatrend SR+Jardiance; Dilatrend SR; Jardiance; Matching placebo of Dilatrend SR

Eligibility Criteria

Inclusion Criteria

• Patients must agree to the study protocol and provide written informed consent
• Outpatients ≥ 20 years of age, male or female
• Patients with severe functional tricuspid regurgitation

• TR whose vena contracta ≥0.7cm or central jet area > 10 square cm and which lasted > 6 months under medical treatment
• LV ejection fraction ≥ 50%
• Dyspnea of NYHA functional class II or III

Exclusion Criteria

• History of hypersensitivity or allergy to the study drugs, drugs of similar chemical classes, as well as known or suspected contraindications to the study drug
• Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor
• Significant left-sided valve disease
• Left ventricular ejection fraction <40%
• Marked bradycardia (<50 beats/min) or 2nd or 3rd degree AVB, sinus node dysfunction
• Severe pulmonary hypertension: TR Vmax >4m/s at screening (including Cor pulmonale)
• Medical history of hospitalization within 6 weeks
• Current acute decompensated heart failure or dyspnea of NYHA functional class IV
• Symptomatic hypotension and/or a SBP < 90 mmHg at screening Estimated GFR < 30 mL/min/1.73 square m
• History of ketoacidosis, Type 1 diabetes
• Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portocaval shunt.
• Acute coronary syndrome, stroke, severe peripheral artery disease or major CV surgery or PCI within 3 months
• History of severe pulmonary disease (asthma, COPD with bronchial hypersensitivity)
• Secondary hypertension such as pheochromocyotoma
• Acute pulmonary thromboembolism
• Variant angina, vocal cord edema, severe allergic rhinitis
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method
• Pregnant or nursing (lactating) women
• Contraindication for MRI

• Presence of pacemaker or ICD, implanted metallic objects, claustrophobia
• Severe beat-to-beat variation
• Galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption
• Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chong Kun Dang Pharmaceutical Corporation

UNKNOWN

Sponsor Role: collaborator

Asan Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Duk-Hyun Kang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

DUK HYUN KANG

Role: PRINCIPAL_INVESTIGATOR

Asan Medical Center

Locations

Asan Medical Center

Seoul, , South Korea

Samsung Medical Center

Seoul, , South Korea

Seoul National University Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

2020-0127

Identifier Type: -

Identifier Source: org_study_id